SURPASS-2

A phase 3 study comparing the safety and efficacy of the drug tirzepatide versus the drug semaglutide as additional therapy to the drug metformin in patients with type 2 diabetes. (SURPASS-2 )

Study title

Background

As not all people with Type 2 diabetes benefit from current diabetes treatments, there is a need to develop new and improved therapies. The new drug tirzepatide differs to other available treatments in the way it works.

Study Aims

The main aim of the study is to find out whether tirzepatide administered once weekly by self-administered subcutaneous injection is as good as or better than semaglutide once-weekly injection at treating Type 2 diabetes.

Study Summary

The study is a 47-week randomized controlled trial with four treatment arms. The three doses of tirzepatide (5mg, 10mg or 15mg) are double-blinded so the patient/research team will not know which dose they are taking during the study, while the semaglutide 1mg arm is open-label.

Study Progress 

The study has completed recruitment and is currently ongoing.

Funding and Sponsorship 

The study is a commercial study funded and sponsored by Eli Lilly.

Study Publications

The study results will be published by the sponsor after study completion.

Research Team

Principal Investigator: Professor Melanie Davies

Research Nurse: Penny Donley